Stigma and efficacy beliefs regarding opioid use disorder treatment and naloxone in communities participating in the HEALing Communities Study intervention Authors: Nicky Lewis, Barry Eggleston, Redonna K Chandler, Dawn Goddard-Eckrich, Jamie E Luster, Dacia D Beard, Emma Rodgers, Rouba Chahine, Philip M Westgate, Shoshana N Benjamin, JaNae Holloway, Thomas Clarke, R Craig Lefebvre, Michael D Stein, Donald W Helme, Jennifer Reynolds, Sharon L Walsh, Darcy Freedman, Nabila El-Bassel, Kara Stephens, Anita Silwal, Michelle Lofwall, Janet E Childerhose, Hilary L Surratt, Brooke N Crockett, Amy L Farmer, James L David, Laura Fanucchi, Judy Harness, Ben Wilburn, Kelli Bursey, Kristin Mattson, Sarah Mann, Rebecca D Jackson, Aimee Shadwick, Katherine Calver, Deborah Chassler, Jennifer Kimball, Nancy Regan, Jeffrey H Samet Published: 2024 ABSTRACT AbstractBackgroundThe HEALing Communities Study (HCS) included health campaigns as part of a community-engaged intervention to reduce opioid-related overdose deaths in 67 highly impacted communities across Kentucky, Massachusetts, New York, and Ohio. Five campaigns were developed with community input to provide information on opioid use disorder (OUD) and overdose prevention, reduce stigma, and build demand for evidence-based practices (EBPs). An evaluation examined the recognition of campaign messages about naloxone and whether stigma and efficacy beliefs regarding OUD treatment and naloxone changed in HCS intervention communities.MethodsData were collected through surveys offered on Facebook/Instagram to members of communities participating in the HCS intervention and wait-list control communities.ResultsParticipants in HCS intervention communities reported a reduction in stigma regarding OUD and increased efficacy beliefs regarding naloxone associated with recognition of campaign messages. However, this finding is cautiously interpreted as there was no clear evidence for recognition differences between the treatment/control conditions.ConclusionStudy findings indicate associations between campaign message recognition and positive outcomes. Results also highlight possible challenges concerning evaluations of social media campaigns using conventional evaluation techniques.Trial registrationClinicalTrials.gov NCT04111939. Background The U.S. continues to experience high rates of fatal drug overdoses; in 2022, nearly 105,000 individuals experienced fatal overdose [1]. Most are attributable to illicitly manufactured fentanyl and fentanyl analogues. One potential intervention to combat this epidemic is the use of health campaigns to reduce stigma around opioid use disorder (OUD) and increase support for evidence-based practices (EBPs) [2]. Most existing health campaigns addressing opioid overdose have not provided evidence of their effectiveness [3]. Health campaign evaluations are necessary to determine their effectiveness and to ensure wise use of community resources [4]. Health campaigns’ influence on knowledge, attitudes, and behavior The influence of health campaigns on behavior depends largely on the context of the overall health intervention [5]; for example, whether the intervention has existing public support, public belief the intended behavior change is effective and feasibly achieved, and cultural acceptability. Other important elements include who the campaign focuses on and the content of the messages themselves. A review of health communication and social marketing literature has generated EBPs that can guide the design of campaigns regarding opioid overdose [6]. Among these practices are the following: behavior change as an explicit goal; using formative research in design and planning; focusing on homogeneous populations; using multiple dissemination channels; increasing the frequency of conversations about specific health issues in social networks; prompting policy discussions that lead to effective policy changes; and ensuring the availability and access to services and resources to promote behavior change. These practices can increase public belief that the intended behavior change resulting from campaigns is achievable. The HEALing Communities Study (HCS) The HCS is a multi-site, parallel-group, cluster randomized wait-list comparison trial testing the impact of the Communities That HEAL intervention (CTH) on opioid-related overdose deaths and other outcomes in 67 communities across four states (Kentucky, Massachusetts, New York, and Ohio). Communities were randomized to either receive the CTH first (Wave 1; n = 34) or serve as the wait-list control group (Wave 2; n = 33) to receive the CTH after the HCS comparison period was completed [7]. The CTH intervention includes three components: (a) a process for community coalition-driven decision making around the deployment/expansion of EBPs guided by a data-driven approach to reduce opioid overdose deaths [8], (b) a set of EBPs with demonstrated efficacy and effectiveness in reducing overdoses and treating OUD [9], and (c) health campaigns to drive demand for EBPs, reduce stigma toward OUD treatment, and inform people about availability of OUD-related services [2]. Priority target groups for the campaigns included community leaders, people at risk for an overdose or with OUD, and family and friends of those at risk. Community-specific dissemination strategies were developed with local coalitions to reach these priority groups. One community initially randomized to receive the intervention decided not to participate in the study and withdrew before the CTH intervention began. Over 27 months (April 1, 2020—June 30, 2022), five campaigns were sequentially launched in the Wave 1 (W1) intervention communities in the following order: overdose education and naloxone distribution (OEND); stigma related to medications for OUD (MOUD); MOUD Awareness; MOUD Treatment Retention; and Community Choice (i.e., communities chose to repeat a prior campaign). HCS community coalitions each selected Communications Champions who worked with research staff to develop community-specific content and disseminate campaign materials, using distribution plans. There were over 1,400 materials created for the first campaign (OEND; Campaign 1) that included print, billboards, and news stories, in addition to social media advertising. Campaign messaging had a consistent appearance and branding across the four states. Recruitment for a Campaign Evaluation Questionnaire (CEQ) was conducted through social media (e.g., Facebook/Instagram) at regular intervals. The purpose of the CEQ was to assess campaign recognition and attitudes in W1 communities and less frequently in the Wave (W2) wait-list control communities. Social media served as a recruitment tool to assess recognition and impact of the campaigns in HCS communities. Research questions This study examines two primary research questions: 1) did W1 community members accurately report recognition of (i.e., ‘having seen’) naloxone advertisements from the HCS campaigns compared to W2 community members that were in the control condition (i.e., did not have HCS campaigns underway), and 2) did Wave 1 community members show evidence of a reduction in individual-level stigma regarding OUD and improved efficacy beliefs regarding OUD treatment and naloxone? Methods This study was designed as a longitudinal comparison of communities within the context of a cluster randomized trial. Of the 67 communities, 34 were randomized to W1, and 33 were randomized to W2 (i.e., wait-list control); W2 received the CTH intervention after the main trial evaluation period was over. One community withdrew immediately after randomization and was excluded from further analysis (i.e., was not treated as randomized). This report focuses on the per protocol population of the remaining 66 communities. All procedures were approved by the single Institutional Review Board Advarra Inc. (Pro00037850 for pilot test; Pro00038088 for final guide). The CEQ, designed by HCS researchers, assessed specific components of stigma regarding OUD treatment and awareness and acceptability of naloxone and MOUD treatment. Recruitment and administration of the cross sectional CEQ survey occurred in W1 communities for approximately 5–6 weeks at each of six time points (i.e., CEQ 1–6), starting at baseline (March 2020; prior to Campaign 1) and then after each campaign (see Table 1 for the CEQ timeline). The CEQ was administered to W2 at baseline and twice thereafter in June—July 2021 and June—August 2022, during which W2 communities had no exposure to the HCS campaigns. Our goal was to obtain ≤ 20 surveys per community at each time point to achieve 80% power based on a two-sided test and a 5% significance level. Recruitment within a community was stopped at n = 20 respondents for each CEQ to avoid oversampling of more populated (urban) areas. Table 1Participant characteristics stratified by iteration of Campaign Evaluation Questionnaire (CEQ)1.Characteristic, statisticIterationOverallCEQ1CEQ2CEQ3CEQ4CEQ5CEQ63/30/20-4/22/209/2/20-9/30/201/13/21-2/18/216/14/21-7/21/2111/8/21-12/17/217/1/22-8/11/22 Number of Respondents 1,1789097261,5186761,7336,740 Number of Communities Represented 63333366336666 Intervention, n(%) Wave 1600 (50.9%)909 (100.0%)726 (100.0%)830 (54.7%)676 (100.0%)900 (51.9%)4,641 (68.9%)Wave 2578 (49.1%)NANA688 (45.3%)NA833 (48.1%)2,099 (31.1%) Research Site, n(%) Kentucky370 (31.4%)124 (13.6%)97 (13.4%)392 (25.8%)109 (16.1%)449 (25.9%)1,541 (22.9%)Massachusetts184 (15.6%)120 (13.2%)104 (14.3%)235 (15.5%)130 (19.2%)249 (14.4%)1,022 (15.2%)New York229 (19.4%)246 (27.1%)237 (32.6%)393 (25.9%)180 (26.6%)497 (28.7%)1,782 (26.4%)Ohio395 (33.5%)429 (46.1%)288 (39.7%)498 (32.8%)257 (38.0%)538 (31.0%)2,395 (35.5%) Geographic Location, n(%) Rural191 (16.2%)200 (22.0%)186 (25.6%)445 (29.3%)189 (28.0%)475 (27.4%)1,686 (25.0%)Urban987 (83.8%)709 (78.0%)540 (74.4%)1,073 (70.7%)487 (72.0%)1,258 (72.6%)5,054 (75.0%) Age, n(%) 18–34 Years427 (36.4%)217 (25.3%)161 (23.7%)266 (20.0%)108 (17.5%)391 (22.8%)1,570 (24.6%)35–49 Years316 (27.0%)221 (25.7%)187 (27.5%)308 (23.2%)164 (26.5%)476 (27.8%)1,672 (26.2%)50–64 Years310 (26.5%)295 (34.3%)218 (32.1%)478 (36.0%)225 (36.4%)535 (31.2%)2,061 (32.3%)65–74 Years104 (8.9%)109 (12.7%)102 (15.0%)218 (16.4%)100 (16.2%)248 (14.5%)881 (13.8%)75+ Years15 (1.3%)17 (2.0%)12 (1.8%)59 (4.4%)21 (3.4%)63 (3.7%)187 (2.9%) Race/Ethnicity, n(%) Non-Hispanic White961 (83.6%)683 (81.2%)552 (84.1%)1,067 (83.2%)500 (82.0%)1,387 (83.0%)5,150 (82.9%)Non-Hispanic Black79 (6.9%)75 (8.9%)49 (7.5%)88 (6.9%)47 (7.7%)115 (6.9%)453 (7.3%)Non-Hispanic Other54 (4.7%)45 (5.4%)25 (3.8%)61 (4.8%)34 (5.6%)74 (4.4%)293 (4.7%)Hispanic55 (4.8%)38 (4.5%)30 (4.6%)66 (5.1%)29 (4.8%)96 (5.7%)314 (5.1%) Gender, n(%) Male297 (25.4%)179 (20.8%)137 (20.1%)324 (24.4%)131 (21.2%)350 (20.4%)1,418 (22.3%)Female847 (72.5%)666 (77.4%)530 (77.9%)981 (74.0%)475 (76.9%)1,327 (77.2%)4,826 (75.7%)Other25 (2.1%)15 (1.7%)13 (1.9%)21 (1.6%)12 (1.9%)41 (2.4%)127 (2.0%) Education, n(%)